Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Cancer. 2010 Jun 15;116(12):3006-14. doi: 10.1002/cncr.25044.
Selecting an appropriate staging system is crucial to predict the outcome of patients with hepatocellular carcinoma (HCC). The optimal prognostic model for HCC is under intense debate. This study investigated the prognostic ability of the 5 currently used staging systems, Barcelona Clinic Liver Cancer (BCLC), Cancer of the Liver Italian Program (CLIP), Japan Integrated Scoring (JIS) system, tumor-node-metastasis (TNM), and Tokyo score, for HCC.
Between 2002 and 2008, 1713 prospectively enrolled HCC patients were compared for their long-term survival by using the Akaike information criterion (AIC) according to the staging or scoring methods of these 5 models.
The mean and median follow-up duration was 18 and 14 months, respectively. Among all patients, the CLIP staging system had the lowest AIC value in comparison with other systems in the Cox proportional hazards model, followed by the Tokyo score, JIS score, BCLC staging system, and TNM staging system. Patients undergoing curative treatment had a significantly better survival in comparison with patients undergoing noncurative treatment (P < .001). When the predictive accuracy of the staging systems was analyzed according to treatment strategy, the CLIP staging system had the lowest AIC value and remained the best prognostic model in patients undergoing curative (801 patients) and noncurative (912 patients) treatment.
The CLIP staging system is the best long-term prognostic model for HCC in a cohort of patient with early to advanced stage of HCC. Its predictive accuracy is independent of the treatment strategy. Selecting an optimal staging system is helpful in improving the design of future clinical trials.
选择合适的分期系统对于预测肝细胞癌(HCC)患者的预后至关重要。目前,对于 HCC 的最佳预后模型仍存在争议。本研究探讨了目前使用的 5 种分期系统(巴塞罗那临床肝癌分期系统、癌症肝脏意大利分期系统、日本综合评分系统、肿瘤-淋巴结-转移分期系统和东京评分系统)对 HCC 的预后能力。
在 2002 年至 2008 年间,对 1713 例 HCC 患者进行前瞻性评估,根据这 5 种模型的分期或评分方法,使用赤池信息量准则(AIC)比较其长期生存情况。
平均和中位随访时间分别为 18 个月和 14 个月。在所有患者中,与其他系统相比,CLIP 分期系统在 Cox 比例风险模型中的 AIC 值最低,其次是东京评分系统、JIS 评分系统、BCLC 分期系统和 TNM 分期系统。接受根治性治疗的患者与接受非根治性治疗的患者相比,生存情况显著更好(P <.001)。当根据治疗策略分析分期系统的预测准确性时,CLIP 分期系统在接受根治性(801 例)和非根治性(912 例)治疗的患者中具有最低的 AIC 值,并且仍然是最佳的预后模型。
CLIP 分期系统是预测 HCC 患者长期预后的最佳模型,适用于早期到晚期 HCC 患者。其预测准确性独立于治疗策略。选择最佳的分期系统有助于改善未来临床试验的设计。